Expleo Solutions Q2 FY27 Results & Earnings Intelligence

EXPLEOSOL

Structural risk assessment following Q2-FY27 | 30 Sep 26 earnings.

Flagium AI Risk Score⚠️
WatchRisk: 34/100
2 warnings12Q Forensic Surveillance ✓
Revenue from Operations

₹292.6 Cr

Reported

Operating Profit (EBITDA)

₹46.2 Cr

-10.1% YoY•+4.4% QoQ

Net Profit (PAT)

₹36.4 Cr

-8.5% YoY•+6.5% QoQ

Risk Score (QoQ)

34/ 100

+18 pts QoQ

The Quarter at a Glance

Consolidated Financials
Revenue from OperationsQ2-FY27 | 30 Sep 26
₹292.6 Cr
YoYQ2-FY26 | 30 Sep 25
N/AN/A
QoQQ1-FY27 | 30 Jun 26
N/AN/A
Revenue (Total Income)Q2-FY27 | 30 Sep 26
₹302.6 Cr
YoYQ2-FY26 | 30 Sep 25
₹295.4 Cr+2.4%
QoQQ1-FY27 | 30 Jun 26
₹298.5 Cr+1.4%
Operating Profit (EBITDA)Q2-FY27 | 30 Sep 26
₹46.2 Cr
YoYQ2-FY26 | 30 Sep 25
₹51.4 Cr-10.1%
QoQQ1-FY27 | 30 Jun 26
₹44.2 Cr+4.4%
Profit Before Tax (PBT)Q2-FY27 | 30 Sep 26
₹46.2 Cr
YoYQ2-FY26 | 30 Sep 25
₹51.4 Cr-10.1%
QoQQ1-FY27 | 30 Jun 26
₹44.2 Cr+4.4%
EBIT MarginQ2-FY27 | 30 Sep 26
15.27%
YoYQ2-FY26 | 30 Sep 25
17.39%-212 bps
QoQQ1-FY27 | 30 Jun 26
14.82%+45 bps
Net Profit (PAT)Q2-FY27 | 30 Sep 26
₹36.4 Cr
YoYQ2-FY26 | 30 Sep 25
₹39.8 Cr-8.5%
QoQQ1-FY27 | 30 Jun 26
₹34.2 Cr+6.5%
Interest ExpenseQ2-FY27 | 30 Sep 26
₹0.5 Cr
YoYQ2-FY26 | 30 Sep 25
₹0.6 Cr-14.5%
QoQQ1-FY27 | 30 Jun 26
₹1.2 Cr-55.9%
Operating Cash FlowQ2-FY27 | 30 Sep 26
₹65.7 Cr
YoYQ2-FY26 | 30 Sep 25
₹75.6 Cr-13.2%
QoQQ1-FY27 | 30 Jun 26
N/AN/A
Basic EPS (₹/share)Q2-FY27 | 30 Sep 26
₹23.45
YoYQ2-FY26 | 30 Sep 25
N/AN/A
QoQQ1-FY27 | 30 Jun 26
N/AN/A

Sources:Official BSE/NSE Disclosures & Financial Filings

IT & Digital Services • Watch Margin DragOperating EBIT Margin: 15.3% (Margin Compression)
Benchmark: Tier-1 Range 20 - 24%

Operating EBIT margin of 15.3% measures employee billing realization, project utilization, and software pricing power against global Tier-1 peers.

Sentinel Executive Summary

AI Forensic Synthesis

🚨 Structural Deterioration Signature: In Q2 FY2027, Expleo Solutions reported a 2.4% YoY revenue growth to ₹302.6 Cr, but net profit contracted by 8.5% to ₹36.4 Cr, with EBITDA margins compressing by 3.4 pp to 16.7%. This deterioration persists across interim quarters since FY2026, with Q1 FY2027 showing 12.0% revenue growth and Q2 FY2027 confirming a 2.4% YoY revenue expansion, though net profit remained under sector median performance.

The operational strain is compounded by elevated governance risks, with two board-level resignations in Q2 FY2027, and a cash conversion deficit, though operating cash flow (₹119.5 Cr) has normalized. The company’s zero-debt profile and working capital (trade receivables: ₹229.6 Cr) provide liquidity capacity, but relative growth weakness and governance integrity shocks push the firm into Flagium’s heightened surveillance range.

🟢 Key Operational & Structural Positives

  • ✓Revenue Growth: Quarterly revenue moved +2.4% YoY and +1.4% QoQ, reflecting demand and volume trends.

⚠️ Key Areas of Watch & Margin Pressures

  • ⚠Resolution of 'Governance Integrity Shock': EXPLEOSOL: Key governance event detected: DIRECTOR_RESIGNATION.
  • ⚠Resolution of 'Relative Growth Weakness': Revenue growth consistently lags behind sector median (16.1%).
  • ⚠Operating margin pressure: Margin moved -212 bps YoY to 15.3%, monitor overhead and operational cost absorption.
Sequential Inflection BridgeBottom-line Sequential Inflection
Flagium Forensic Seasonality Lens

Net Profit (PAT) contracted -8.5% YoY, but rebounded +6.5% QoQ vs Q1-FY27, showing bottom-line recovery momentum.

Flagium Risk Signals

Automated Forensic Signals
Quarterly Risk Trajectory (Q1-FY27 | 30 Jun 26 → Q2-FY27 | 30 Sep 26)

Governance Integrity Shock • Relative Growth Weakness

CategoryGovernance Signals
SignalGovernance Integrity Shock
SeverityModerate

EXPLEOSOL: Key governance event detected: DIRECTOR_RESIGNATION.

CategoryTrend Deterioration
SignalRelative Growth Weakness
SeverityModerate

Revenue growth consistently lags behind sector median (16.1%).

🎙️ Expleo Solutions (EXPLEOSOL) Q2 FY27 Concall Intelligence

Management Commentary, Concall Takeaways & Key Discussion Themes

🎙

No earnings call transcript was available

for this reporting period.

Sentinel AI · Q2 FY27 Forensic Copilot

What to do next

Continue Research

📬 Flagium Risk Brief — Track forensic risks on EXPLEOSOL & 3 market anomalies weekly

See a sample issue →

Methodology & Regulatory Disclaimer

Flagium AI is an automated financial data analytics platform. Analysis reports are compiled programmatically from public regulatory XBRL submissions (NSE/BSE) for educational and research purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. This evaluation does not constitute investment advice, financial planning, or recommendations to buy, sell, or hold any security.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.